Andrew Lowy

Andrew Lowy is a pancreatic cancer surgeon-scientist who has made significant contributions to both surgical techniques and molecular targeting strategies in pancreatic cancer. His research has focused on KRAS oncogene biology and the development of KRAS inhibitors as a therapeutic approach in pancreatic ductal adenocarcinoma. He has led clinical studies on neoadjuvant and adjuvant chemotherapy regimens in resectable and borderline resectable disease. His dual expertise in surgery and molecular oncology makes him a unique contributor to the field.